The Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in a Complete Response Letter (CRL) for etripamil nasal spray (Cardamyst ™ ), an investigational ...

FDA accepts Milestone's response on Cardamyst nasal spray, sets new PDUFA date; company raises $52.5 million to support ...

The Food and Drug Administration approved a new epinephrine nasal spray last fall and a version for smaller children this month. But Texas law needs a wording change for it to be used by school ...

A nasal spray called FluMist has been approved by the U.S. Food and Drug Administration as an alternative to the traditional injection of the flu vaccine.

FluMist is the first vaccine to prevent influenza, more commonly known as the flu, that does not need to be administered by a ...

Today’s health headlines: ketamine nasal sprays offer a new option for people with treatment-resistant depression. Plus, how ...

The treatment, a nasal spray called esketamine, is the subject of a new research paper published in the American Journal of Psychiatry.

New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® ...

A “MOLECULAR shield” placed in the nose could prevent hay fever symptoms, a study suggests. Scientists have engineered an ...

The Food and Drug Administration approved the first needle-free alternative to the EpiPen, a single-use epinephrine nasal spray for emergency treatment of allergic reactions, including anaphylaxis.

This new nasal spray delivers medicine the same way as a nasal allergy spray like Flonase or the same way as Narcan for people experiencing an opioid overdose.